Elevated pretreatment interleukin-10 serum level is an International Prognostic Score (IPS)-independent risk factor for early treatment failure in advanced stage Hodgkin lymphoma
- 1 January 2008
- journal article
- research article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 49 (11) , 2091-2098
Abstract
Early treatment failure is still a clinical challenge despite high cure rates in Hodgkin lymphoma (HL) patients. To identify the biological risk factors predicting early treatment failure, we performed a retrospective case–control study. Forty-seven pretherapeutic serum samples were available from 47 advanced stage HL patients with early treatment failure and from 47 matched controls in complete remission. All patients were treated within German Hodgkin Study Group phase 3 trials. Matching was done according to treatment, stage, age, gender, International Prognostic Score (IPS) and histological subtype. Pretreatment serum levels of 30 cytokines, chemokines and soluble receptors were determined using immunoassays and flow cytometer based cytometric bead arrays. Only interleukin-10 serum levels were significantly associated with early treatment failure after statistical correction for multitesting (paired-sign test, p = 0.0008). In summary, pretherapeutic interleukin-10 levels are associated with early treatment failure within 12 months after the end of treatment in advanced stage HL independently from known clinical factors such as age or IPS.Keywords
This publication has 26 references indexed in Scilit:
- New Strategies for the Treatment of Advanced-Stage Hodgkin's LymphomaHematology/Oncology Clinics of North America, 2007
- The AP1-dependent secretion of galectin-1 by Reed–Sternberg cells fosters immune privilege in classical Hodgkin lymphomaProceedings of the National Academy of Sciences, 2007
- Plasma Cytokine and Soluble Receptor Signature Predicts Outcome of Patients With Classical Hodgkin's Lymphoma: A Study From the Groupe d'Etude des Lymphomes de l'AdulteJournal of Clinical Oncology, 2007
- From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potentialBlood, 2005
- Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphomaBlood, 2004
- Long-Term Cause-Specific Mortality of Patients Treated for Hodgkin’s DiseaseJournal of Clinical Oncology, 2003
- Standard and Increased-Dose BEACOPP Chemotherapy Compared with COPP-ABVD for Advanced Hodgkin's DiseaseNew England Journal of Medicine, 2003
- New Prognostic Score Based on Treatment Outcome of Patients With Relapsed Hodgkin's Lymphoma Registered in the Database of the German Hodgkin's Lymphoma Study GroupJournal of Clinical Oncology, 2002
- The Role of Chemokines in Hodgkin's DiseaseLeukemia & Lymphoma, 2000
- A Prognostic Score for Advanced Hodgkin's DiseaseNew England Journal of Medicine, 1998